Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NANO-X IMAGING LTD (Nanox) SEC filings page for ticker NNOX provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ. Nanox files an annual report on Form 20-F and furnishes current reports on Form 6-K that cover topics such as capital raises, financial results, shareholder meetings, and significant business developments related to its medical imaging and AI platform.
Recent Form 6-K filings describe a registered direct offering of ordinary shares under an effective shelf registration statement on Form F-3, including the related placement agency agreement, purchase agreement, and legal opinions. Other 6-K reports furnish press releases announcing quarterly financial results, non-GAAP financial measures reconciled to GAAP, and notices and proxy materials for the company’s annual general meeting of shareholders. These documents allow investors to review how Nanox funds its operations and how it reports performance across its Nanox.ARC, radiology services, and AI solutions divisions.
Through this page, users can also track filings that reference Nanox’s imaging systems and AI solutions, including disclosures about commercialization activities, acquisitions such as VasoHealthcare IT, and integration of AI software with health IT infrastructure. The exhibits to these filings may include agreements, opinions, and other materials that provide additional context on Nanox’s operations and capital structure.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand items such as registered offerings, financial updates, or meeting notices. Real-time updates from EDGAR ensure that new 6-Ks, 20-Fs, and related registration statements appear promptly, while dedicated sections highlight ownership and insider-related filings when available. This combination of original SEC documents and AI-generated insights helps investors and researchers analyze NNOX regulatory information more efficiently.
Nano-X Imaging Ltd. executive Ofir Koren, General Manager of the ARC Division, filed an initial ownership report showing direct holdings of ordinary shares and stock options. The filing lists stock options over 100,000, 25,000 and 33,500 ordinary shares with exercise prices of $49.6800, $17.6300 and $11.5200, expiring between 2031 and 2033. It also describes restricted share units granted in April 2024 and February 2026, which vest over time in scheduled installments.
Nano-X Imaging Ltd. executive Aharon Cohen Tamar, EVP & Chief Marketing Officer, reported his initial equity holdings. He directly holds ordinary shares, including 39,474 ordinary shares, and has 20,000 ordinary shares tied to restricted share units granted on February 5, 2026, which vest 50% after 12 months and 50% after 24 months.
He also holds stock options over ordinary shares: 33,000 at an exercise price of $49.68 expiring on January 18, 2031, 17,000 at $17.63 expiring on March 28, 2032, 8,000 at $17.63 expiring on May 16, 2032, and 55,000 at $11.52 expiring on May 23, 2033. The 2021 grant is fully vested, while the 2022 and 2023 grants vest in 16 equal quarterly installments.
NANO‑X IMAGING LTD filed a Form F-3 to register up to $100,000,000 of ordinary shares, warrants and debt securities for offer and sale from time to time. The registration permits primary offerings by the Company through underwriters, dealers, agents or direct sales after the registration becomes effective. The prospectus states proceeds are intended for funding research, general corporate purposes and other commercial efforts. As of December 31, 2025, 69,590,228 ordinary shares were issued and outstanding. The prospectus describes the Company’s Nanox System (Nanox.ARC, Nanox.CLOUD), FDA 510(k) clearances, CE mark, go‑to‑market plans in the U.S. and EU, AI and teleradiology assets, and that offerings will be detailed in prospectus supplements.
Nano-X Imaging Ltd. reports that the U.S. FDA has granted 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for its Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. TAP2D generates a 2D image directly from a 3D tomosynthesis scan, giving radiologists both 3D and 2D views from a single scan without additional radiation.
The company highlights this clearance as an important step in its regulatory strategy to position Nanox.ARC systems as primary diagnostic solutions and to work toward removing adjunctive use in the United States. The software enhancement can be delivered remotely to existing Nanox.ARC installations as part of ongoing imaging improvements.
Nano-X Imaging Ltd reports a registered direct offering to a single institutional investor of 3,826,530 ordinary shares at $3.92 per share. The transaction is expected to generate approximately $15.0 million in gross proceeds after deducting placement agent fees and other offering expenses payable by the company, which will be used for working capital and general corporate purposes.
Titan Partners Group LLC, a division of American Capital Partners, LLC, acted as sole placement agent under a placement agency agreement. For 10 days after the placement agency agreement date, Nanox agreed not to issue or agree to issue additional ordinary shares or equivalents, or file new registration statements other than limited exceptions. Company officers and directors entered 30‑day lock-up agreements after the closing, restricting sales or other disposals of ordinary shares and related securities without the placement agent’s consent.
Nano-X Imaging Ltd is issuing 3,826,530 ordinary shares in a registered direct offering to a single institutional investor at $3.92 per share, raising gross proceeds of about $15.0 million. After placement agent fees and expenses, the company expects net proceeds of approximately $14.2 million, which it plans to use for general working capital and corporate purposes.
The offering implies an immediate dilution of about $2.35 per share to the new investor, based on an as adjusted net tangible book value of $1.57 per share as of September 30, 2025. As context, there were 65,382,892 ordinary shares outstanding as of September 30, 2025, so this deal modestly increases the share count. Nanox also highlights recent milestones, including expanded FDA clearances, a CE mark in Europe for its Nanox.ARC system, and a proposed acquisition of VHC IT for up to $800,000 to support U.S. deployment of its AI imaging solutions.
Nanox Imaging Ltd entered into a securities purchase agreement with a single institutional investor for a registered direct offering of 3,826,530 ordinary shares at $3.92 per share. The agreement includes customary representations, warranties, and indemnification provisions for both the company and the purchaser. Closing of the offering is expected on November 25, 2025, subject to customary closing conditions. The company also furnished a related press release as an exhibit and reminded readers that any forward-looking statements are subject to significant business, regulatory, geopolitical, and macroeconomic risks.
NANO-X IMAGING LTD filed a Form 6-K reporting that it issued a press release on November 20, 2025, furnishing its latest financial results. The company explains that the press release includes both U.S. GAAP financial information and additional non-GAAP financial measures that exclude certain expenses required under GAAP, and directs readers to the press release for details on those adjustments.
The GAAP financial statement tables in the press release are incorporated by reference into Nano-X Imaging’s existing registration statements on Form F-3 (File No. 333-271688) and Form S-8 (File No. 333-248322), linking the updated financial information to previously filed offerings and equity compensation plans.
NANO-X IMAGING LTD reported that it will hold its Annual General Meeting of Shareholders on December 22, 2025 at 3:00 p.m. Israel time (8:00 a.m. EST) at its offices in Ofer Tech Park, Petach Tikva, Israel. Shareholders are being provided with a Notice and Proxy Statement and a Proxy Card, which are attached as exhibits to this report. The company also states that the information in this report is incorporated by reference into its existing registration statements on Form F-3 (File No. 333-271688) and Form S-8 (File No. 333-248322).